https://www.selleckchem.com/products/ca-170.html
Anti-hepsin pretreatment combined with adeno-associated virus-transduced donor hepatocytes expressing human FIX, a hyperfunctional FIX variant, resulted in plasma FIX levels similar to those associated with mild hemophilia, which protected hemophilia B mice from major bleeding episodes for 50 days after transplantation. Furthermore, anti-hepsin pretreatment and repeated transplantation resulted in extending the therapeutic period by 30 days relative to the IgG control. Thus this anti-hepsin strategy improved the therapeutic effect of hep
Like
Comment
Share
